Phase 2 Glioma Clinical Trials
74 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 74 trials
Recruiting
Phase 1Phase 2
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Malignant Glioma
National Cancer Institute (NCI)132 enrolled127 locationsNCT05099003
Recruiting
Phase 2
Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
BRAF V600 MutationLow-grade GliomaLow Grade Glioma of Brain+1 more
University of California, San Francisco96 enrolled5 locationsNCT07110246
Recruiting
Phase 2
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Central Nervous System DiseasesBrain CancerGlioblastoma Multiforme (GBM)+4 more
Black Diamond Therapeutics, Inc.162 enrolled4 locationsNCT07326566
Recruiting
Phase 1Phase 2
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
ParagangliomaPheochromocytomaMeningioma+4 more
Perspective Therapeutics300 enrolled19 locationsNCT05636618
Recruiting
Phase 2
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Gastric CancerOvarian CancerCholangiocarcinoma+7 more
National Cancer Institute (NCI)320 enrolled1 locationNCT06503146
Recruiting
Phase 2
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Neuroendocrine TumorsParagangliomaPheochromocytoma+1 more
National Cancer Institute (NCI)130 enrolled1 locationNCT03206060
Recruiting
Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Pancreatic Neuroendocrine TumorVon Hippel-Lindau DiseasePheochromocytoma/Paraganglioma+2 more
Merck Sharp & Dohme LLC322 enrolled84 locationsNCT04924075
Recruiting
Phase 2
Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
Recurrent GliomaRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 Glioma+1 more
National Cancer Institute (NCI)30 enrolled27 locationsNCT05859334
Recruiting
Phase 1Phase 2
A Study of Mirdametinib in People With Central Nervous System Tumors
GliomaCentral Nervous System Tumors
Memorial Sloan Kettering Cancer Center26 enrolled7 locationsNCT07539441
Recruiting
Phase 2
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
CNS TumorHigh Grade Glioma
St. Jude Children's Research Hospital52 enrolled4 locationsNCT06528691
Recruiting
Phase 1Phase 2
Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
GliomaCNS Tumor, AdultCNS Tumor, Childhood
Centre Leon Berard70 enrolled11 locationsNCT07243470
Recruiting
Phase 2
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+7 more
Nationwide Children's Hospital120 enrolled21 locationsNCT05843253
Recruiting
Phase 2
A Study Utilizing Escitalopram in Glioma Patients
GliomaGlioma of Brain
University of Nebraska20 enrolled1 locationNCT03728673
Recruiting
Phase 1Phase 2
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
MeningiomaRecurrent Diffuse Intrinsic Pontine GliomaHigh Grade Glioma+10 more
Nationwide Children's Hospital65 enrolled4 locationsNCT05278208
Recruiting
Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Brain TumorBrain CancerGlioblastoma+6 more
Northwell Health37 enrolled1 locationNCT02800486
Recruiting
Phase 1Phase 2
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
OsteosarcomaEwing SarcomaNeuroblastoma+4 more
Milton S. Hershey Medical Center289 enrolled10 locationsNCT06465199
Recruiting
Phase 1Phase 2
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NeoplasmsBrain TumorGlioblastoma+3 more
NaviFUS Corporation10 enrolled1 locationNCT06329570
Recruiting
Phase 2
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
High Grade GliomaDiffuse Intrinsic Pontine GliomaRecurrent Medulloblastoma
Nationwide Children's Hospital120 enrolled12 locationsNCT05096481
Recruiting
Phase 2
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
Diffuse Intrinsic Pontine Gliomas (DIPG)Progressive DIPGRefractory DIPG+2 more
Nationwide Children's Hospital60 enrolled20 locationsNCT06838676
Recruiting
Phase 1Phase 2
H3K27M-specific Immune Effector Cells Targeting DMG/DIPG
Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
Shenzhen Geno-Immune Medical Institute30 enrolled1 locationNCT07501156